CYTOSHRINK: A randomized phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with ipilimumab/nivolumab for metastatic kidney cancer.
Aly‐Khan A. Lalani, Gregory Russell Pond, Shankar Siva, William Chu et autres
416 Background: Patients (pts) presenting with de novo metastatic renal cell carcinoma (mRCC) have a poor prognosis. The role of cytoreductive nephrectomy (CN) is uncertain in these pts. Stereotactic body radiation therapy (SBRT) provides a convenient method for cytoreduction of the primary …
ca, au (code pays fourni par la source)